Novo Nordisk considers upgrading its New York listing to boost US visibility
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
According to a report by the Financial Times, as cited by Chinese financial data provider Jin10, Danish weight-loss drug manufacturer Novo Nordisk (NVO.N) has indicated it does not rule out upgrading its listing status on the New York Stock Exchange. The potential move is aimed at increasing the company's visibility and profile in the U.S. market. This follows a similar action taken earlier this year by its British competitor, AstraZeneca. The report highlights a trend among European pharmaceutical companies seeking to enhance their presence and investor access in the United States.
Source report
According to the Financial Times, Novo Nordisk (NVO.N) has not ruled out upgrading its listing status in New York. The move is aimed at raising the Danish weight-loss drug manufacturer's profile in the U.S. market.
This follows a similar step taken earlier this year by its British competitor, AstraZeneca.
Source
金十数据Neutral / independent